{{Rsnum
|rsid=10802866
|Gene=FMN2
|Chromosome=1
|position=240377711
|Orientation=plus
|GMAF=0.4307
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=FMN2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 31.9 | 47.8 | 20.4
| HCB | 20.4 | 47.4 | 32.1
| JPT | 10.6 | 39.8 | 49.6
| YRI | 8.2 | 37.4 | 54.4
| ASW | 14.0 | 45.6 | 40.4
| CHB | 20.4 | 47.4 | 32.1
| CHD | 12.8 | 52.3 | 34.9
| GIH | 28.7 | 50.5 | 20.8
| LWK | 1.8 | 31.8 | 66.4
| MEX | 13.8 | 50.0 | 36.2
| MKK | 7.7 | 43.6 | 48.7
| TSI | 32.4 | 46.1 | 21.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10802866
|Name_s=
|Gene_s=FMN2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00005. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109387
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10802866
|overall_frequency_n=76
|overall_frequency_d=126
|overall_frequency=0.603175
|n_genomes=46
|n_genomes_annotated=0
|n_haplomes=70
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}